NCT05160480
A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
Enrolling by Invitation
Not specifiedAges 18+ObservationalUniversity of California, DavisInvestigator-initiated
~9 participants
Updated 2026-03-10 on ClinicalTrials.gov
What's tested:Total-body PET imaging
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
measure radiotracer avidity
Measured over One study imaging visit lasting up to 10 hours
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Lorenzo Nardo, MD · PRINCIPAL_INVESTIGATOR · University of California, Davis
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Persons \>18 yo with suspected prostate cancer metastasis
Prior imaging study (CT, and/or MRI and/or Bone scan and/or Fluciclovine scan) suspicious for metastatic disease, obtained within 4 months from the research scan date.
Persons \> 18 yo suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors (NETs)
Prior DOTATATE PET/CT scan suspicious for tumor obtained not earlier than 4 months from the research scan date.
Exclusion
Adults unable to consent
Pregnant/lactating persons
Prisoners
Unable to lie supine for up to 90 minutes at different timepoints in the PET scanner
Uncontrolled claustrophobia
Any significant medical condition that in the opinion of the investigator would prevent the participant from participating and/or adhering to study related procedures or interfere with participant safety
What this trial measures
- measure radiotracer avidityOne study imaging visit lasting up to 10 hours
measure radiotracer avidity, i.e. standardized uptake value measurements (SUV max and mean) of tumor and normal tissue as a function of time with 18F-PSMA, 18F-FES, 68Ga DOTATATE in a total-body PET scanner among men with suspected prostate cancer metastasis, patients suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors, and patients with recurrent or metastatic breast cancer.